Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
68,828.53 +1,430.09 (+2.12%) CMC Crypto 200
1,389.80 +59.20 (+4.45%)
GILD Jan 2026 67.500 call
| Previous close | 12.90 |
| Open | 12.90 |
| Bid | 14.75 |
| Ask | 15.30 |
| Strike | 67.50 |
| Expiry date | 2026-01-16 |
| Day's range | 12.90 - 12.90 |
| Contract range | N/A |
| Volume | |
| Open interest | 203 |
Business WireGilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
FOSTER CITY, Calif., July 25, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s second quarter 2024 financial results and provide a business update.
Business WireGilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
FOSTER CITY, Calif., July 25, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data from its innovative HIV treatment portfolio and research pipeline, including a broad range of investigational and marketed agents with varied dosing frequencies and administration methods. The findings presented at the 25th International AIDS Conference (AIDS 2024) reflect a portfolio and future-looking pipeline focused on person-centered drug development strategies to help addre
Business WireFull Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
FOSTER CITY, Calif., July 24, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced full efficacy and safety results from its pivotal, Phase 3 PURPOSE 1 trial. Detailed data from the trial’s interim analysis announced in June showed that lenacapavir, the company’s twice-yearly injectable HIV-1 capsid inhibitor, demonstrated zero infections, 100% efficacy and superiority to background HIV incidence for the investigational use of HIV prevention in cisgender women (women assigned female at bir
